top of page

Screen Shot 2021-01-12 at 11.44.35 AM.pn

Search

A2A Wins AI Quickfire

A2A Pharma
May 16, 2019
1 min read

Updated: Feb 7, 2020

A2A Wins AI Quickfire Challenge at JLABS @ Toronto

LEARN MORE

Recent Posts

A2A TACC3 Program Clinical Progress in Womens Cancers

May 27, 2025 - A2A Pharmaceuticals a clinical stage oncology company with the lead asset AO-252, a PPI inhibitor of TACC3 which is a 1st...

FDA Clearance of IND Application for TACC3 PPI Inhibitor A2A-252 in Women's Cancer

FDA Clearance of IND Application for TACC3 PPI Inhibitor A2A-252 in Women's Cancer

A2A co-founded biomea Fusion raises $56M

Biomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations...

Comments

bottom of page